Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Diabetes

Diabetes

Subtypes of Diabetes

Type 2 Diabetes 229 Type 1 Diabetes 44 Prediabetes 27 Diabetic Macular Edema 12 Diabetic Nephropathy 9 Diabetic Ketoacidosis 8 Diabetic Peripheral Neuropathy 5 Diabetic Foot Osteomyelitis 3 Hypoglycemia 3 Diabetic neuropathy 2 Glycemic Control 2 New-Onset Diabetes 2 Post-transplant diabetes mellitus 2 Proliferative diabetic retinopathy 2 Diabetic emergencies 1 Diabetic osteoporosis 1 Diabetic Wound Healing 1 Glycemic management 1 Hyperglycemia in pregnancy 1 Hyperglycemic Crisis 1 Hyperosmolar hyperglycemic state 1 Impaired Awareness of Hypoglycemia 1 Insulin-Dependent Diabetes 1 Non-proliferative diabetic retinopathy 1 Normal Hypoglycemia Awareness 1 Painful diabetic peripheral neuropathy 1 Plantar Diabetic Foot Ulcers 1 Postprandial Hyperglycemia 1 Steroid-induced diabetes 1 Steroid-induced hyperglycemia 1 Type 2 Diabetes Mellitus with Mild Cognitive Impairment 1 Type 3 Diabetes Mellitus 1 Type 3c Diabetes 1 Diabetic Retinal Disease 0 Diabetic sensorimotor polyneuropathy 0 Hemichorea associated with non-ketotic hyperglycemia 0

457 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Diabetes

750 trials tracked for Diabetes: 270 in phase 3 or 4 and 101 with published results. The most-cited published study has 7395 citations.

750Trials tracked
270Phase 3 & 4
0Recruiting
101With published results
Phase distribution
Phase 4 86 Phase 3 184 Phase 2 59 Phase 1 21 Other / NA 400
  1. Phase 3 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Completed · 7,395 cited
  2. Phase 3 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Completed · 6,709 cited
  3. Phase 3 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Completed · 1,960 cited
  4. Phase 4 Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus Completed · 1,810 cited
  5. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 776 cited
  6. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes Completed · 718 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Completed · 588 cited
  2. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 581 cited
  3. Phase 3 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed · 569 cited
  4. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Completed · 478 cited
  5. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Completed · 473 cited
  6. Phase 3 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Completed · 447 cited
  7. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Completed · 447 cited
  8. Phase 3 Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Completed · 421 cited
  9. Phase 3 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Completed · 410 cited
  10. Phase 3 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Completed · 402 cited
  11. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Completed · 397 cited
  12. Phase 3 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Completed · 394 cited
  13. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Completed · 369 cited
  14. Phase 3 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed · 363 cited
  15. Phase 3 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Completed · 350 cited
  16. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment Completed · 342 cited
  17. Phase 3 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes Completed · 337 cited
  18. Phase 3 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Completed · 293 cited
  19. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed · 283 cited
  20. Phase 3 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Completed · 275 cited
  21. Phase 4 Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI Completed · 273 cited
  22. Phase 3 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Completed · 255 cited
  23. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes Completed · 254 cited
  24. Phase 4 Stop Atherosclerosis in Native Diabetics Study Completed · 247 cited
  25. Phase 3 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Completed · 224 cited
  26. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes Completed · 220 cited
  27. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Completed · 217 cited
  28. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 210 cited
  29. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes Completed · 207 cited
  30. Phase 4 Reducing Total Cardiovascular Risk in an Urban Community Completed · 193 cited
  31. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus Completed · 189 cited
  32. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes Completed · 177 cited
  33. Phase 4 Effect of Testosterone in Men With Erectile Dysfunction Completed · 162 cited
  34. Phase 3 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Completed · 134 cited
  35. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Completed · 126 cited
  36. Phase 3 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes Completed · 123 cited
  37. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Completed · 119 cited
  38. Phase 3 Insulin Resistance Intervention After Stroke Trial Completed · 108 cited
  39. Phase 3 The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy Completed · 106 cited
  40. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Completed · 105 cited
  41. Phase 4 Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life. Completed · 97 cited
  42. Phase 4 Acute Effect of Exenatide on Brain Glucose Metabolism Completed · 96 cited
  43. Phase 3 RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects Completed · 84 cited
  44. Phase 4 Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient Completed · 78 cited

Showing the 50 most-cited and recently-updated of 750 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Diabetes: what the trials found

Albiglutide 30 mg was associated with significant differences in the time to first occurrence of Major Adverse Cardiovascular Events (MACE) during cardiovascular follow-up 17 and for MACE or urgent revascularization for unstable angina 17. However, no significant difference was found in the time to adjudicated CV death 17.

The use of antiplatelet agents was associated with a reduction in low-density lipoprotein cholesterol 20, a decrease in systolic blood pressure 20, and a statistically significant change in HbA1c levels 20.

Sildenafil citrate (open label) was associated with improvements in the Erectile Function Domain Score of the International Index of Erectile Function (IIEF) 21, as well as changes in the Psychological General Well-Being Index Score (PGWBI) 21 and the Positive Affects Ratio (PAR) 21.

Recent results — preliminary, needs further review

  • Ertugliflozin 15 mg was evaluated for its effect on blood pressure, with results showing significant values across multiple measurements 1.
  • The DASH4D diet was associated with specific Systolic Blood Pressure (SBP) outcomes 4.
  • Smart insulin pens and CGM were associated with a decrease in HbA1c percentage, an increase in the percentage of glucose values in range, and a negligible change in the percentage of glucose values below range 12.
  • The SDH Tool was associated with various DM Key Test outcomes 14.
  • Other interventions under investigation or recently studied include standard of care insoles 2, VasQ 3, surgical procedures like Carotid Endarterectomy 9, and various programs such as the Diabetes Prevention Program 6, Culinary Medicine Program 10, and Family Check Up Heart 15.

For the clinician treating this condition

  • Albiglutide 30 mg demonstrated significant impacts on MACE timelines in patients with cardiovascular follow-up, though it did not significantly affect CV death rates.
  • Antiplatelet agents showed multi-faceted benefits including improvements in lipid profiles, blood pressure, and HbA1c levels.
  • Technological interventions like smart insulin pens combined with CGM were associated with improved glycemic control (HbA1c) and increased time-in-range.

AI synthesis of 13 cited trials, updated Jun 19, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Diabetes: current evidence & treatments

Diabetes mellitus is associated with a high burden of microvascular and macrovascular complications, including diabetic neuropathy, retinopathy, nephropathy, and peripheral arterial disease, as observed in adult Ugandans 2. Chronic hyperglycemia contributes to multi-level nerve damage across peripheral, autonomic, and central nervous systems, driven by metabolic and vascular disturbances such as oxidative stress and microvascular dysfunction 6. Immunometabolic dysregulation, including activation of the polyol pathway, advanced glycation end products, and mitochondrial dysfunction, creates a pro-inflammatory microenvironment that drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy 1.

Pharmacological interventions show varying benefits in diabetes management. Semaglutide reduces the risk of kidney decline or death in type 2 diabetes with chronic kidney disease 10 and improves metabolic health in schizophrenia patients on antipsychotics 15. GLP-1 receptor agonists may reduce cognitive decline in type 2 diabetes patients with dementia 13 and are associated with a lower risk of serious liver events compared with DPP-4 inhibitors 25. SGLT2 inhibitors are associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes 3. Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis 16. Metformin is associated with higher lactate concentrations during exercise in adults with prediabetes and type 2 diabetes 8. Insulin degludec/liraglutide ranks highest for HbA1c reduction among fixed-ratio combinations 20. Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in diabetic macular edema 9.

Emerging technologies and genetic insights are advancing diabetes care. Transcriptomic analysis identified 337 high-confidence type 2 diabetes-associated genes in human pancreatic islets, with an IsletDysfunctionScore showing significant separation between non-diabetic and type 2 diabetes islets 5. AI-driven cardiovascular risk prediction in type 2 diabetes shows promise but is limited by bias and lack of diversity 23. Pancreatic tissue engineering for type 1 diabetes faces a vascularization hurdle 7. CAR technology is being explored for type 1 diabetes among other conditions 11. scFv-based biologics show potential for immunomodulation in both type 1 and type 2 diabetes 19. Adipose-derived stem cell exosomes are being investigated for diabetic foot ulcers, but efficacy data are lacking 14.

Key drugs in the evidence

metformin 6 glucagon-like peptide-1 receptor agonists 3 SGLT2 inhibitors 3 sodium-glucose cotransporter 2 inhibitors 3 GLP-1 receptor agonists 3 semaglutide 3 rivaroxaban 2 statins 2 direct oral anticoagulants 2 aspirin 1

Latest findings

AI-generated synthesis of 17 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Intraduodenal Lauric Acid and Tryptophan Reduce Postprandial Glucose in Small Diabetes Trial
Nutrition & Obesity Medicine RCT
Intraduodenal Lauric Acid and Tryptophan Reduce Postprandial Glucose in Small Diabetes Trial Two Nutrients, Delivered Deep, Calm Blood Sugar
A small RCT in 11 men with type 2 diabetes found that a combined intraduodenal infusion of lauric acid and L-tryptophan before a meal reduce…
Two nutrients that did nothing on their own slowed the stomach and cut the meal-time glucose spike when paired.
Apr 13, 2026
Higher dietary phytochemical index associated with better sleep quality in adults with type 2 diabetes
Oncology RCT
Higher dietary phytochemical index associated with better sleep quality in adults with type 2 diabetes Plant-Rich Plates Linked to Better Sleep for Diabetics
A cross-sectional study of 675 adults with type 2 diabetes found that higher dietary phytochemical index (DPI) scores were associated with b…
A diet rich in plant-based foods tracked with longer sleep and lower inflammation in adults with type 2 diabetes.
Frontiers Apr 13, 2026
Review of quercetin in metabolic diseases shows promise but lacks clinical validation
Diabetes & Endocrinology RCT
Review of quercetin in metabolic diseases shows promise but lacks clinical validation Review suggests quercetin may have multiple beneficial effects on metabolic conditions
This review evaluates quercetin for conditions including diabetes, obesity, and gout.
A natural compound found in fruits and vegetables shows promise for managing type 2 diabetes, obesity, and fatty liver disease, though human…
Frontiers Apr 13, 2026
Protocol compares Mediterranean and low-carb diets for diabetes remission in Lebanese adults
Diabetes & Endocrinology RCT
Protocol compares Mediterranean and low-carb diets for diabetes remission in Lebanese adults Two Diets Go Head-to-Head for Type 2 Diabetes Remission
This randomized controlled trial protocol will compare a low-calorie Mediterranean-style diet to a low-calorie, low-carbohydrate diet for di…
A trial in Lebanon will test if a low-calorie Mediterranean or low-carb diet can put type 2 diabetes into remission, focusing on real-world …
Frontiers Apr 13, 2026
Systematic review shows PCOS in obese women links to high MASLD and 2–4 fold increased cardiovascular and diabetes risks
Diabetes & Endocrinology Sys. Review
Systematic review shows PCOS in obese women links to high MASLD and 2–4 fold increased cardiovascular and diabetes risks PCOS Is Not Just About Your Ovaries Anymore
This systematic review evaluated the extra-ovarian health impacts of polycystic ovary syndrome (PCOS) in women, with a focus on those with o…
Polycystic ovary syndrome is being rethought as a full-body metabolic condition, and that shift could change how — and by whom — it's treate…
Frontiers Apr 13, 2026
Existing cognitive frailty models show good discrimination in older adults with diabetes but suffer high bias risk
Diabetes & Endocrinology Meta-analysis
Existing cognitive frailty models show good discrimination in older adults with diabetes but suffer high bias risk Can A Simple Score Predict Memory Loss In Older Diabetics?
This systematic review and meta-analysis evaluated 2,947 diabetic patients to assess the predictive performance and risk of bias of existing…
Simple risk scores may soon flag older diabetics who are sliding toward combined memory and muscle decline — but today's tools still need wo…
Frontiers Apr 13, 2026
Elevated peripheral HIF-1α levels associated with higher fasting glucose and HbA1c in patients with type 2 diabetes mellitus
Nutrition & Obesity Medicine Meta-analysis
Elevated peripheral HIF-1α levels associated with higher fasting glucose and HbA1c in patients with type 2 diabetes mellitus A Hidden Blood Signal May Expose Failing Insulin Cells
This systematic review and meta-analysis examined 5,979 patients with type 2 diabetes mellitus to assess the association between peripheral …
A blood protein called HIF-1α rises when insulin-making cells fail in type 2 diabetes, offering a new way to track disease progression.
Frontiers Apr 13, 2026
QingYun7 dietary intervention improves glycemic control in patients with type 2 diabetes
Diabetes & Endocrinology Cohort
QingYun7 dietary intervention improves glycemic control in patients with type 2 diabetes Herbal Diet Changes Gut Bacteria to Lower Blood Sugar
This longitudinal cohort study involving 385 patients with type 2 diabetes evaluated the QingYun7 (QY7) dietary herbal intervention.
A herbal mix changed gut bacteria to lower blood sugar in people with type 2 diabetes, offering a new way to manage the condition.
Frontiers Apr 13, 2026
Biological age acceleration transitions associated with higher type 2 diabetes and mortality risk in UK Biobank cohort
Diabetes & Endocrinology
Biological age acceleration transitions associated with higher type 2 diabetes and mortality risk in UK Biobank cohort Your Body May Be Aging Faster Than Your Birthday Says
An observational cohort study of 13,751 UK Biobank participants found that transitions to accelerated biological aging were associated with …
Two people can share a birthday but age very differently inside, and that hidden gap may quietly raise the odds of diabetes and early death.
medRxiv Apr 13, 2026
Network meta-analysis finds acupuncture therapies may improve glycemic parameters in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis finds acupuncture therapies may improve glycemic parameters in type 2 diabetes Body Acupuncture Beats Standard Care for Blood Sugar
A systematic review and network meta-analysis of 12,231 patients with T2DM compared various acupuncture therapies to conventional treatment.
Adding specific acupuncture types to your current diabetes plan may lower blood sugar more effectively than medicine alone.
Apr 12, 2026
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Frontiers Apr 12, 2026
Technology-based interventions showed greater weight loss in women with prior gestational diabetes compared to control groups
Diabetes & Endocrinology Meta-analysis
Technology-based interventions showed greater weight loss in women with prior gestational diabetes compared to control groups Your Phone Could Be Your Shield Against Diabetes After Pregnancy
This systematic review and meta-analysis evaluated technology-based diabetes prevention interventions versus control in 1,257 women with a h…
For new mothers at high risk for type 2 diabetes, digital tools on a smartphone may offer a practical, private way to build healthier habits…
Apr 12, 2026

Questions about Diabetes

How many pregnant women were in the Lp(a) gestational diabetes risk study?

The Lp(a) gestational diabetes risk study included 922 pregnant women with normal glucose tolerance (NGT) after propensity score matching.

Full answer →
What is the link between diabetes and the immune system fighting tuberculosis?

Diabetes weakens the immune system's ability to control tuberculosis, increasing risk of infection and worse outcomes.

Full answer →
Can surgery help heal wounds caused by gouty tophi in patients with diabetes?

Yes, surgery can help heal wounds from gouty tophi, but diabetes increases the risk of delayed healing and infection, so careful preoperative management is essential.

Full answer →
How does having diabetes affect the risk of infection after spinal surgery?

Yes, diabetes significantly increases the risk of infection after spinal surgery, with studies showing roughly 3-4 times higher odds of surgical site infection.

Full answer →
Can immune checkpoint inhibitors cause diabetes mellitus in patients?

Yes, immune checkpoint inhibitors can cause diabetes mellitus, often presenting suddenly with diabetic ketoacidosis.

Full answer →
Do voltage-dependent potassium channels play a role in diabetes research findings?

Yes, voltage-dependent potassium (Kv) channels help regulate insulin secretion, and their dysfunction is linked to diabetes. Research explores them as potential drug targets.

Full answer →
Does switching to integrase inhibitors increase the risk of developing diabetes in HIV patients?

Yes, switching to integrase inhibitors (INSTIs) is linked to an increased risk of developing diabetes in people with HIV, based on recent studies.

Full answer →
Can Ganoderma lucidum polysaccharides help manage diabetes and related complications?

Yes, Ganoderma lucidum polysaccharides (GLPs) show potential to help manage diabetes and its complications through antioxidant, anti-inflammatory, and blood sugar-lowering effects, but human trials are needed.

Full answer →
See all 8 questions about Diabetes →